METHOD OF ISOLATION OF PURE CULTURE OF VASCULAR ENDOTHELIAL CELLS, MEDIUM FOR MAINTAINING CHARACTERISTICS OF VASCULAR ENDOTHELIAL CELLS, AND CULTURE METHOD INCLUDING SAME
20220378845 · 2022-12-01
Inventors
Cpc classification
A61K35/44
HUMAN NECESSITIES
C12N2501/165
CHEMISTRY; METALLURGY
C12N2501/115
CHEMISTRY; METALLURGY
C12N5/0607
CHEMISTRY; METALLURGY
International classification
Abstract
The present specification provides: a method of isolation of a pure culture of vascular endothelial cells, the method capable of isolating homogeneous endothelial cells adhered to a matrix for a specific time in a cell line of an endothelial cell lineage differentiated from human pluripotent stem cells; a medium for maintaining characteristics of vascular endothelial cells, comprising high-purity vascular endothelial cells isolated through the method, 4 ng/ml to 6 ng/ml of FGF2, 5 ng/ml to 10 ng/ml of EGF, 10 ng/ml to 30 ng/ml of VEGF-A, 20 ng/ml to 50 ng/ml of ascorbic acid, and DMEM/F-12 as active ingredients; and a culture method comprising same.
Claims
1. A method of separating pure vascular endothelial cells, the method comprising steps of: obtaining a cell line of an endothelial cell lineage differentiated from human pluripotent stem cells from a differentiation medium; filtering the obtained cell line using a filter; culturing the filtered cell line on a matrix; and separating homogenous endothelial cells attached to the matrix from the cultured cell line.
2. The method of claim 1, wherein the filter has a pore spacing in the range of 20 μm to 40 μm.
3. The method of claim 1, wherein the matrix comprises at least one of collagen, fibrin, fibronectin, vitronectin, Matrigel, gelatin, laminin, heparin, polylysine, and hyaluronic acid.
4. The method of claim 3, wherein the matrix is collagen and comprises 0.1 mg/ml of the collagen.
5. The method of claim 1, wherein culturing the filtered cell line is performed in DMEM/F-12 medium containing cell growth factors and ascorbic acid.
6. The method claim 5, wherein the cell growth factor comprises at least one of fibroblast growth factor-1 (FGF-1), FGF-2 (bFGF), FGF-3, FGF-4, FGF-5, FGF-6, epidermal growth factor (EGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), transforming growth factor-α (TGF-α), TGF-β, angiopoietin 1, angiopoietin 2, erythropoietin, neuropilin, IGF-1, osteopoline, pleiotrophin, activin, endothelin 01 and vascular endothelial growth factor-A (VEGF-A).
7. The method of claim 1, wherein the culturing the filtered cell line comprises seeding the filtered cell line on two matrices.
8. The method of claim 1, wherein the culturing the filtered cell line is performed for 4 hours to 20 hours.
9. The method of claim 1, wherein the homogeneous endothelial cells express CDH5 and VWF.
10. The method of claim 9, wherein the gene expression level of CDH5 is 12 times higher than before the separation.
11. The method of claim 9, wherein the gene expression level of VWF is 2 times higher than before the separation.
12. A vascular endothelial cell comprising 98% or more of homogenous endothelial cells that are separated by the method of claim 1 and expressing CDH5 and VWF.
13. A cell therapeutic composition for preventing or treating cardiovascular diseases, the composition comprising vascular endothelial cells having a purity of 98% or more according to claim 12.
14. The composition of claim 13, wherein the cardiovascular disease includes at least one of ischemic heart disease, heart failure, hypertensive heart disease, arrhythmia, cardiomyopathy, ventricular septal defect, congenital heart disease, myocardial infarction, pericardial disease, stroke, peripheral vascular disease, aneurysm, arteriosclerosis, hypertension, angina pectoris, and myocardial infarction.
15. A culture method of maintaining vascular endothelial cell characteristics, the method comprising: first seeding a human pluripotent stem cells (hPSCs) by suspending the human pluripotent stem cells with an induction medium on a plate; first culturing the first seeded stem cells to differentiate the first seeded stem cells into mesoderm cells in an induction medium; second culturing the first seeded stem cells to differentiate the first cultured cells into endothelial cells in a differentiation medium; selecting cells of the vascular endothelial cell lineage from the second cultured cells; second seeding by suspending the selected vascular endothelial cells with a maintenance medium on a plate; and passage culturing the second seeded vascular endothelial cells to proliferate the second seeded vascular endothelial cells in the maintenance medium.
16. The method of claim 15, wherein the induction medium contains 4 ng/ml to 6 ng/ml of FGF2 and 2 μM to 4 μM of CHIRR99021.
17. The method of claim 15, wherein the differentiation medium contains 4 ng/ml to 6 ng/ml of FGF2, 5 ng/ml to 10 ng/ml of EGF, 10 ng/ml to 30 ng/ml of VEGF-A and 20 ng/ml to 30 ng/ml of DLL4.
18. The method of claim 15, wherein the maintenance medium contains 4 ng/ml to 6 ng/ml of FGF2, 5 ng/ml to 10 ng/ml of EGF, 10 ng/ml to 30 ng/ml of VEGF-A, and 20 ng/ml to 50 ng/ml of ascorbic acid.
19. The method of claim 15, wherein the human pluripotent stem cells include at least one of embryonic stem cells, induced pluripotent stem cells (iPSC) and somatic cell nuclear transfer stem cells (SCNT).
20. The method of claim 15, wherein the first culturing is performed to change the medium every day for 3 days.
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
BEST MODES FOR CARRYNG OUT THE INVENTION
[0084] Advantages and features of the present invention and methods of achieving the same become apparent with reference to the examples described below in detail in conjunction with the accompanying drawings. However, the present invention is not limited to the examples disclosed below, but is embodied in various different forms, and only these examples allow the disclosure of the present invention to be complete and are provided to fully inform those of ordinary skill in the art to which the present invention belongs, the scope of the invention. The present invention is only defined by the scope of the claims. As used herein, the term “differentiation” means that cells develop at the level of a composite or individual of a specific cell or tissue having a specific function.
[0085] As used herein, the term “proliferation” refers to an increase in the number of cells and is used in the same sense as growth.
[0086] As used herein, the term “renewal ability” may mean the ability of a cell to make an exact copy of itself, and when the regenerative ability is improved, the cell's proliferative ability may be excellent.
[0087] Method of Separating Pure Vascular Endothelial Cells
[0088] Hereinafter, with reference to
[0089]
[0090] Referring to
[0091] Then, the cells of the mesoderm lineage may be differentiated into cell lines of the endothelial cell lineage in the differentiation medium by changing the differentiation medium every day for 11 days to 14 days. In this case, the differentiation medium may be a DMEM/F-12 medium containing a growth factor and DLL4, a Notch signaling ligand. Here, delta-like ligand 4 (DLL4) is a signaling substance in the process of angiogenesis and may be associated with an increase in the expression level of endothelial cell markers.
[0092] Then, homogenous endothelial cells may be isolated from the cell line of the differentiated endothelial cell lineage by using the method of separating pure vascular endothelial cells according to an example of the present invention. More specifically, referring to
[0093] First, in step of obtaining a cell line of an endothelial cell lineage differentiated from human pluripotent stem cells from a differentiation medium (S110), a proteolytic enzyme method may be used to obtain a cell line of the endothelial cell lineage differentiated from the differentiation medium. More specifically, referring to
[0094] Next, in step of filtering the obtained cell line using a filter (S120), a filter may be used to have a pore spacing in the range of 20 μm to 40 μm, thereby separating cells of a certain size. More specifically, referring to
[0095] Then, in step of culturing the filtered cell line on the matrix (S130), the cell line may be divided and seeded on the matrix. More specifically, referring to
[0096] In addition, in step of culturing the filtered cell line on the matrix (S130), it may be cultured for 4 hours to 20 hours. More specifically, referring to
[0097] Accordingly, vascular endothelial cells expressing CDH5 and VWF markers may adhere to a matrix containing 0.1 mg/ml collagen for 4 hours to 20 hours, and when culture is performed for more than 20 hours, a different type of cells having an expression pattern of the marker other than the vascular endothelial cell expressing CDH5 and VWF markers may adhere. Accordingly, the culturing step for the method of separating pure vascular endothelial cells according to an example of the present invention may be performed for 4 hours to 20 hours but is not limited thereto. The culture time may be adjusted according to the type of matrix.
[0098] Furthermore, the matrix used in step of culturing the filtered cell line on a matrix (S130) may include at least one of collagen, fibrin, fibronectin, vitronectin, Matrigel, gelatin, laminin, heparin, polylysine, and hyaluronic acid. However, it may contain 1 mg/ml or less, preferably 0.1 mg/ml of collagen. However, the matrix is not limited thereto, and any material to which vascular endothelial cells may be selectively attached may be used without limitation.
[0099] Furthermore, in step of culturing the filtered cell line on a matrix (S130), the cell line of the filtered endothelial cell lineage may be cultured in DMEM/F-12 medium containing cell growth factors and ascorbic acid. In this case, the growth factor refers to a substance that may promote cell division, cell growth and differentiation, and may include at least one of fibroblast growth factor-1 (FGF-1), FGF-2 (bFGF), FGF-3, FGF-4, FGF-5, FGF-6, epidermal growth factor (EGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), transforming growth factor-α (TGF-α), TGF-β, angiopoietin 1, angiopoietin 2, erythropoietin, neuropilin, IGF-1, osteopoline, pleiotrophin, activin, endothelin 01 and vascular endothelial growth factor-A (VEGF-A), but is not limited thereto.
[0100] Furthermore, in the culture environment conditions, the temperature may be 36° C. to 38° C., preferably 36.5° C. to 37.5° C., the supply oxygen (O.sub.2) may be 1% to 25%, and the supply carbon dioxide (CO.sub.2) may be 1% to 15%
[0101] Next, in step of separating homogenous endothelial cells attached to the matrix from the cultured cell line (S140), high-purity vascular endothelium containing 98% or more of expression positive cells for a marker specifically expressed in vascular endothelial cells may be isolated. More specifically, referring to
[0102] Furthermore, the expression level of markers for vascular endothelial cells may be increased by the method of separating pure vascular endothelial cells according to an example of the present invention. More specifically, the gene expression level of CDH5, which is a specific marker for vascular endothelial cells, may be 12 times higher than before separation by the method of separating pure vascular endothelial cells. In addition, the gene expression level of VWF, which is a specific marker for vascular endothelial cells, may be twice as high as before separation by the method of separating pure vascular endothelial cells.
[0103] Again, referring to
[0104] There is an effect of producing high-purity vascular endothelial cells having homogeneous characteristics from human pluripotent stem cells in high yield by the method of separating pure vascular endothelial cells according to an example of the present invention.
[0105] Confirmation of the Filter Effect in the Method of Separating Pure Vascular Endothelial Cells According to an Example of the Present Invention
[0106] Hereinafter, the effect of the filter in the method of separating pure vascular endothelial cells according to an example of the present invention is described in detail with reference to
[0107]
[0108] Referring to
[0109] First, referring to
[0110] Furthermore, referring to
[0111] Furthermore, referring to
[0112] As a result of the above, in the method of separating pure vascular endothelial cells according to an example of the present invention, the filter is used to increase the number of positive cells expressing CDH5, a specific marker for vascular endothelial cells and to separate cells having morphologically equivalent shape. Accordingly, the use of the filter causes an effect that may provide higher purity vascular endothelial cells.
[0113] Confirmation of Purity of Vascular Endothelial Cells Separated by the Method of Separating Pure Vascular Endothelial Cells According to an Example of the Present Invention
[0114] Hereinafter, the confirmation of purity of vascular endothelial cells separated by the method of separating pure vascular endothelial cells according to an example of the present invention is described in detail with reference to
[0115]
[0116] First, referring to
[0117] In addition, when the pure separation of the present invention is not performed, the positive expression level of vascular endothelial cells for the PECAM1 marker is 16.9%, and when the pure separation is performed, the level is 42.6%.
[0118] In addition, when the pure separation of the present invention is not performed, the positive expression level of vascular endothelial cells for the TEK marker is 11.6%, and when the pure separation is performed, the level is 28.8%.
[0119] In addition, when the pure separation of the present invention is not performed, the positive expression level of vascular endothelial cells for the KDR marker is 2.6%, and when the pure separation is performed, the level is 16.0%.
[0120] In addition, when the pure separation of the present invention is not performed, the positive expression level of vascular endothelial cells for the VWF marker is 71.6%, and when the pure separation is performed, the level is 98.4%.
[0121] Furthermore, referring to
[0122] Furthermore, referring to
[0123] In addition, the gene expression for the VWF marker, which is characteristically expressed in vascular endothelial cells with 98% purity, by pure separation, is shown to be twice higher than before pure separation.
[0124] Meanwhile, the mRNA expression level of vascular endothelial cells for the KDR marker is shown to be high than before pure separation. This KDR marker is expressed in the early stage of differentiation of vascular endothelial cells, and these characteristics are gradually lost when differentiated into mature vascular endothelial cells. Meanwhile, VWF marker is a substance which is not expressed in the early stage of differentiation but is expressed in the process of differentiation into mature vascular endothelial cells. Accordingly, an endothelial cell colony with a high mRNA expression level for KDR before pure separation may mean that undifferentiated vascular endothelial cells are included. Furthermore, an endothelial cell colony with a high mRNA expression level for VWF after pure separation may mean that fully differentiated and mature vascular endothelial cells are included.
[0125] For example, referring to
[0126] At this time, since human pluripotent stem cells have the characteristics of stem cells, matrix adhesion may be significantly lower than that of other cells, and accordingly, they may be cultured in suspension. However, as stem cells are differentiated into vascular endothelial cells, they lose their characteristics of stem cells and may acquire matrix adhesion to vascular endothelial cells. Accordingly, suspension cells during passage culture still have the characteristics of stem cells with poor matrix adhesion and may mean that they are undifferentiated cells in the early stage of differentiation in which KDR markers are expressed. Furthermore, the adherent cells may refer to mature cells exhibiting the matrix adhesion characteristics of vascular endothelial cells.
[0127] Furthermore, when only mature vascular endothelial cells are separated by the method of separating pure vascular endothelial cells according to an example of the present invention and are passage cultured, it is shown that only adherent cells are present. This may mean that undifferentiated cells do not exist, only mature vascular endothelial cells are seeded, and they proliferate into high-purity vascular endothelial cells.
[0128] As a result of the above, it is confirmed that undifferentiated cells and cells having different characteristics are separated by the method of separating pure vascular endothelial cells according to an example of the present invention, thereby providing high-purity vascular endothelial cells during passage culture. Accordingly, it is possible to provide high-purity vascular endothelial cells in which expression of CDH5 and VWF markers, which are characteristically expressed in vascular endothelial cells, are 98% or more, that is, their purity is 98% or more.
[0129] Culture Method of Maintaining Vascular Endothelial Cell Characteristics
[0130] Hereinafter, a method of maintaining vascular endothelial cell characteristics according to an example of the present invention is described in detail with reference to
[0131]
[0132] Referring to
[0133] Here, in the culture environment conditions, the temperature may be 36° C. to 38° C., preferably 36.5° C. to 37.5° C., the supply oxygen (O.sub.2) may be 1% to 25%, and the supply carbon dioxide (CO.sub.2) may be 1% to 15%.
[0134] More specifically, first, in first seeding step to suspend human pluripotent stem cells with an induction medium and to seed the suspension on a plate (S110), the undifferentiated human pluripotent stem cells are separated from the tissue using a proteolytic enzyme and then suspended with the induction medium, and the suspension is seeded a plate coated with a coating film containing 0.1 mg/ml collagen.
[0135] Here, the proteolytic enzyme refers to an enzyme capable of isolating the intercellular matrix in order to liberate cells or cell aggregates contained in living tissues, and collagenase, dispase, protease, trypsin, etc. may be used in order to separate human pluripotent stem cells from tissues or cells and cell clumps but is not limited thereto.
[0136] Furthermore, the plate is not limited as long as cell culture may be performed, and may include various types of plate such as flasks, tissue culture flasks, dishes, Petri dishes, micro plates, micro well plates, micro slides, chamber slides, chalets, tubes, trays and culture bags, etc. It may include a cell adhesion layer coating film on the upper surface. More specifically, the coating film of the plate may include at least one of collagen, fibronectin, laminin, laminin fragment, vitronectin, basement membrane matrix, gelatin, hyaluronic acid, polylysine, and vitronecrin, and may include 1 mg/ml or less, preferably 0.1 mg/ml of collagen. Accordingly, cell adhesion and extension are promoted by culturing on a plate containing 0.1 mg/ml collagen coating film, thereby increasing the differentiation efficiency of cells of the mesodermal lineage.
[0137] Next, in the first culture step to differentiate the first seeded stem cells into mesoderm cells in an induction medium (S120), the culture is performed using an induction medium containing growth factors, 4 ng/ml to 6 ng/ml of FGF2, as a growth factor, 2 μM to 4 μM of CHIRR99021 as a GSK3β inhibitor and DMEM/F-12 while changing the medium daily for 3 days, thereby inducing differentiation from stem cells to mesodermal lineage cells.
[0138] In this case, Fibroblast growth factor (FGF2) is a growth factor involved in various biological processes such as promotion of division, including cell proliferation and cell differentiation, angiogenesis, bone morphogenesis, and nerve growth.
[0139] In addition, CHIRR99021 is a substance that inhibits the activity of glycogen synthase kinase (GSK). More specifically, as GSK is inhibited, β of the signaling system involved in cell proliferation is not degraded by GSK, and thus the expression level of genes involved in cell proliferation is increased, thereby improving cell survival and proliferation.
[0140] Next, in the second culture step to differentiate the first cultured cells into endothelial cells in a differentiation medium (S130), the culture is performed using a differentiation medium containing growth factors, 4 ng/ml to 6 ng/ml FGF2, 5 ng/ml to 10 ng/ml of EGF, 10 ng/ml to 30 ng/ml of VEGF-A, 20 ng/ml to 30 ng/ml DLL4, as Notch signaling ligand and DMEM/F-12 while changing the medium daily for 11 days to 13 days, thereby inducing differentiation from cells of the mesodermal lineage to the endothelial lineage. Further, in the second culture step to differentiate the first cultured cells into endothelial cells in a differentiation medium (S130), heparin is selectively used to increase the efficiency of differentiation into endothelial cell lineages.
[0141] Here, epidermal growth factor (EGF) is a growth factor capable of promoting cell proliferation, growth, and differentiation by binding to its receptor, and may have an activity to promote proliferation of epithelial cells.
[0142] In addition, vascular endothelial growth factor (VEGF-A) is a signaling substance involved in the formation of the embryonic circulation and vasculogenesis by activating VEGF signaling and may stimulate cell division and cell migration of endothelial cells.
[0143] In addition, delta-like ligand 4 (DLL4) is a signaling substance that affect the Notch receptor which reduces endothelial cell growth and migration, determination of arterial and venous differentiation, determination of tip and stack cell crystallization, and tip cell formation to inhibit excessive angiogenesis, thereby properly regulates angiogenic sprouting. In particular, it is determined that DLL4 is added to regulate the Notch signal, which acts to distinguish and maintain the characteristics of cells to increase the characteristics of vascular endothelial cells, that is, the expression level of markers.
[0144] Next, in step of selecting the second cultured cells as cells of the vascular endothelial cell line (S140), various cell lines differentiated from stem cells, that is, vascular endothelial cells from the endothelial cell lineage, are selected to obtain high-purity vascular endothelial cells. More specifically, a process for selecting pure vascular endothelial cells is described with reference to
[0145] First, referring to
[0146] Then, referring to
[0147] Then, cell selection can be performed to obtain only high-purity vascular endothelial cells. Cell selection is a technology for separating differentiated specific cells with high purity. Flow cell sorting and magnetic cell sorting may be used, but cells can be selected using unique cell characteristics.
[0148] For example, referring to
[0149] Finally, referring to
[0150] Again, as shown in
[0151] Finally, in the passage culture step to proliferate the second seeded vascular endothelial cells in the maintenance medium (S160), the passage culture is performed in the maintenance medium containing growth factors, 4 ng/ml to 6 ng/ml FGF2, 5 ng/ml to 10 ng/ml EGF, and 10 ng/ml to 30 ng of VEGF-A, 20 ng/ml to 50 ng/ml of ascorbic acid and DMEM/F-12, thereby inducing proliferation of vascular endothelial cells
[0152] Here, passage culture may be performed from passages 1 to 4. More specifically, when culturing vascular endothelial cells for more than passages 4, proliferative and differentiation capacity is reduced, and when cultured for a long period of time, cell clumps, etc., may be formed and may be accompanied by chromosomal mutations. Accordingly, referring to
[0153] Furthermore, ascorbic acid is an antioxidant, is involved in procollagen synthesis, and is a cofactor associated with an increase in type 1 collagen production. Ascorbic acid may stimulate and regulate the proliferation of various mesoderm-derived cells such as adipocytes, osteoblasts, and chondrocytes in vitro. Furthermore, when ascorbic acid is added at a specific concentration to the culture medium for mesenchymal stem cells, it acts as a cell growth promoter to increase cell proliferation and to even promote DNA synthesis. However, if the concentration of ascorbic acid is not appropriate, it may rather inhibit the proliferation of cells and have cytotoxicity to cause apoptosis. Accordingly, the appropriate concentration of ascorbic acid capable of improving cell proliferation may be 20 ng/ml to 50 ng/ml but is not limited thereto.
[0154] According to the culture method for maintaining vascular endothelial cell characteristics according to an example of the present invention as described above, there is an effect of producing vascular endothelial cells from human pluripotent stem cells in a high yield.
[0155] Confirmation of Maintenance of Vascular Endothelial Cell Characteristics in the Maintenance Medium According to an Example of the Present Invention
[0156] Hereinafter, the maintenance of vascular endothelial cell characteristics in the maintenance medium according to an example of the present invention is described in detail with reference to
[0157]
[0158] First, referring to
[0159] Accordingly, referring to
[0160] In addition, the positive expression level of vascular endothelial cells for PECAM1 marker according to passage culture in the maintenance medium is 42.8% at passage 1, 43.2% at passage 2, 38.6% at passage 3, and 45.4% at passage 4.
[0161] In addition, the positive expression level of vascular endothelial cells for TEK marker according to passage culture in the maintenance medium is 28.8% at passage 1, 63.4% at passage 2, 30.2% at passage 3, and 17.9% at passage 4.
[0162] In addition, the positive expression level of vascular endothelial cells for the KDR marker according to passage culture in the maintenance medium is 16.0% at passage 1, 61.2% at passage 2, 14.5% at passage 3, and 4.6% at passage 4
[0163] In addition, the positive expression level of vascular endothelial cells for the VWF marker according to passage culture in the maintenance medium is 98.4% at passage 1, 93.1% at passage 2, 88.3% at passage 3, and 97.4% at passage 4.
[0164] Therefore, the vascular endothelial cells according to passage culture in the maintenance medium may refer to high purity differentiated vascular endothelial cells that show high expression levels for CDH5, PECAM1, TEK, KDR and VWF, the markers identified in the vascular endothelial cell positive control group. High purity may mean purity of 98% or more, for example, it may mean that CDH5-positive cell expression is maintained at 98% or more until passage 4.
[0165] Furthermore, referring to
[0166] Furthermore, referring to
CPDL=ln(Nf/Ni)ln2 [Equation 1]
[0167] In this case, Ni means the number of initially seeded cells, Nf means the number of final cells, and In means the natural logarithm.
[0168] The CPDL values of vascular endothelial cells cultured in the maintenance medium are shown to have values in the range of 1 to 2.5 in passages 1 to 4. This may mean that one vascular endothelial cell may proliferate up to 22.5 cells.
[0169] As a result, the proliferation culture of vascular endothelial cells in the culture method of maintaining vascular endothelial cell characteristics according to an example of the present invention may allow the proliferation of uniform vascular endothelial cells without change in cell shape and characteristics despite repeated culturing.
[0170] Comparison of Maintenance of Vascular Endothelial Cell Characteristics According to Media
[0171] Hereinafter, the maintenance of vascular endothelial cell characteristics according to the medium is described in detail with reference to
[0172] Furthermore, Comparative Example 1 is set as a conventional cell culture medium containing hFGF-B, VEGF, R3-IGF-1, ascorbic acid, hEGF, heparin, and GA-1000, Comparative Example 2 is set as the differentiation medium of vascular endothelial cells of the present invention containing 4 ng/ml to 6 ng/ml FGF2, 5 ng/ml to 10 ng/ml of EGF, 10 ng/ml to 30 ng/ml of VEGF-A, 20 ng/ml to 30 ng/ml of DLL4, and DMEM/F-12.
[0173] First,
[0174] More specifically, referring to
[0175] In addition, the positive expression level of vascular endothelial cells for PECAM1 marker is 42.9% in Comparative Example 1, 37.6% in Comparative Example 2, and 59.9% in Example 1.
[0176] In addition, the positive expression level of vascular endothelial cells for TEK marker is 57.3% in Comparative Example 1, 38.8% in Comparative Example 2, and 66.9% in Example 1.
[0177] In addition, the positive expression level of vascular endothelial cells for KDR marker is 19.2% in Comparative Example 1, 69.4% in Comparative Example 2, and 63.8% in Example 1.
[0178] In addition, the positive expression level of vascular endothelial cells for VWF marker is 85.0% in Comparative Example 1, 91.6% in Comparative Example 2, and 96.7% in Example 1.
[0179] Therefore, the vascular endothelial cells according to the culture medium may mean vascular endothelial cells showing expression for CDH5, PECAM1, TEK, KDR and VWF, which are markers identified in the vascular endothelial cell positive control group.
[0180] However, referring to
[0181] Further, referring to
[0182] In addition, the CPDL value of the vascular endothelial cells cultured in Comparative Example 2 is shown to have a value within the range of 1 to 3 in passages 1 to 4. This may mean that one vascular endothelial cell may proliferate up to 23.
[0183] In addition, the CPDL value of the vascular endothelial cells cultured in Example 1 is shown to have a value within the range of 1 to 3.5 in passages 1 to 4. This may mean that one vascular endothelial cell may proliferate up to 23.5. Therefore, the cell growth rate may be the best in Comparative Example 1, which may proliferate the most. However, when the cells rapidly and explosively increase, the cells may form cell clumps, thereby inducing differentiation into unwanted cells.
[0184] Accordingly, referring to
[0185] As a result, the medium of maintaining vascular endothelial cell characteristics according to an example of the present invention does not cause a problem in that the proliferative and regenerative capacity is reduced as the cell culture progresses, and the vascular endothelial cell characteristics are altered along with the mutation, thereby having the effect of proliferating and maintaining the vascular endothelial cells in high purity.
[0186] Accordingly, the present invention may provide uniform vascular endothelial cells, thereby providing vascular endothelial cells that may be stably used in clinical applications.
[0187] Although the examples of the present invention have been described in more detail with reference to the accompanying drawings, the present invention is not necessarily limited to these examples, and various modifications may be made within the scope without departing from the technical spirit of the present invention. Accordingly, the examples disclosed in the present invention are illustrative rather than limiting the technical spirit of the present invention, and the scope of the technical spirit of the present invention is not limited by these examples. Therefore, it should be understood that the examples described above are illustrative in all respects and not restrictive. The protection scope of the present invention should be construed by the following claims, and all technical spirits within the scope equivalent thereto should be construed as being included in the scope of the present invention.
[0188] [National R&D project supporting the present invention]
[0189] [Project unique number] HI16C2211
[0190] [Government department] Ministry of Health and Welfare
[0191] [Research and management institution] Korea Health Industry Development Institute
[0192] [Title of research project] Advanced medical technology development program
[0193] [Title of research task] Determination of the production and therapeutic effect of human induced pluripotent stem cell-derived endothelial cells
[0194] [Contribution rate] 1/1
[0195] [Name of project performance institution] Industry-Academic Cooperation Foundation, Yonsei University
[0196] [Research period] Apr. 1, 2019 to Jan. 31, 2020